Dr. Charlie Bavington GlycoMar Limited www.glycomar.com Exploiting marine glycobiology to advance human health
Company Profile Opportunities for utilisation of shellfish by- products Current products Potential / future products Some global opportunities Challenges
Marine Biotechnology company Established in February 2005 Located Oban, Scotland, at the European Center for Marine Biotechnology Focused on drug discovery through marine glycobiology Alliances with US / European Pharma and biotech companies
GlycoMar - Company Profile European Center for Marine Biotechnology Oban Oban
Marine organism sourcing and holding facilities Chemistry Isolation of new products Purification of new products Characterisation of new products Biology Therapeutic applications Functional characterisation of new products Products Marine glycomolecules Services Anti-inflammatory screening
Fisheries by-product - raw materials opportunities Process waste Offal shell Other species By catch Seafish report SR537, 2001 Fouling organisms (aquaculture) Opportunity Shellfish by-products represent an underutilised, abundant, rich and natural non- mammalian raw material
Shellfish by-product - raw materials opportunities Offal Shell Totals Tonnes % Tonnes % Tonnes % Nephrop s 6169 46 12851 34 19021 37 Crab 2215 16 4239 11 6454 12 Queens 1126 8 4646 12 5771 11 Scallop 2846 21 14559 38 17405 34 Whelk 1105 8 1924 5 3029 6 Totals 13461 100 38220 100 51681 100 % 26 74 Guy Robertson, Shellfish waste arisings in Scotland , 2004
Fisheries by-product - product opportunities Proteins / Amino Acids / Peptides Fish meal, protein isolates, concentrates, hydrolyzates: specialty fertilizer, animal/pet feed, dietary food supplement, flavors, fermentation media Gelatin, collagen: industrial, dietary food supplement, food, cosmetic ingredient Enzymes, growth factors Marine DNA: animal/pet feed, dietary food supplement, cosmetic ingredient
Fisheries by-product - product opportunities Oils Fish oil / omega 3: industrial, animal/pet feed, dietary food supplement, food ingredients Phospholipids: animal/pet feed, dietary food supplement Minerals Fish bone and shell calcium: animal/pet feed, dietary food supplement, food ingredient
Fisheries by-product - product opportunities Chitin/Chitosan: specialty fertilizer, dietary food supplement, food ingredient, cosmetics, medical device Glycosaminoglycans: veterinary, dietary food supplement, human health Protamine: veterinary, human health Taurine: veterinary, human health Carotenoids/astazanthin: animal/pet feed, dietary food supplement Mucins: human health/pharmaceutical
Shellish by-products - product opportunities Shell chitin/chitosan Calcium Carotenoids Offa l Protein DNA Glycomolecules Carotenoids Omega 3 s
Novel by-products applications - potential markets Nutraceutical Additives Capsules Cosmeceutical Dermal augmentation Pharmaceutical Active pharmaceutical ingredients Human health Veterinary health
Examples of shellfish utilisation - Hemcon wound dressings Novel Wound dressing Chitosan based Chitosan produced from shrimp shell chitin Promotes rapid blood clotting Chitin Produced from crustacean shell, e.g. Primex in Iceland
Examples of shellfish utilisation - shrimp enzymes for research Shrimp Alkaline phosphatase Cold adapted Extracted from ice melt Life Science research market Shrimp nuclease Cold adapted Life Science research market Shrimp alkaline phosphatase structure
Examples of shellfish utilisation - glycosaminoglycans for drug discovery Glycosaminoglycans Under development by GlycoMar Polysaccharide molecules present in all tissues Key role in cell-cell and cell-tissue interaction Potential therapeutic application in: Inflammation Immunology cancer metastasis viral infection stem cells
Marine glycosaminoglycans for drug discovery Marine Glycosaminoglycans isolated from: Scallop process by-product Whelk process by-product Mussels Nephrops by-product Fish skin Properties Chemically distinct Anti-inflammatory activity in vitro Markets Drug discovery companies Life Science research Nutraceutical Seeking licensing opportunities
Shellfish by-product utilisation - GlycoMar s strategy Short term (1-3 years) Product discovery - early income from reagent sales, contract research Process development - scalable production process Medium term (3-6 years) Nutraceutical - strategic alliance or licensing Development of immunoactive nutraceticals Development of dermal fillers Preclinical testing of drug candidates Long term (6-10 years) Clinical trials
Shellfish by-product utilisation - challenges Cost of R&D £ M s to bring pharmaceutical to market High risk investment Lead-time for products 3-5 years Nutraceuticals/Cosmeceuticals 10-15 years Pharmaceuticals Regulatory hurdles ABP FDA / EMEA approval Processing facilities
Shellfish by-products represent a valuable raw material Utilisation of shellfish by-products represents an opportunity for the shellfish industry Utilisation of shellfish by products should focus on development of novel technologies Development of waste utilisation technologies requires investment
www.glycomar.com Exploiting marine glycobiology to advance human health
Recommend
More recommend
